Results 111 to 120 of about 2,626 (203)

Comparative efficacy and safety of dupilumab versus newly approved biologics and JAKi in pediatric atopic dermatitis: A systematic review and network meta-analysis.

PLoS ONE
BackgroundThe newly approved biologics and Janus kinase inhibitors (JAKi) for pediatric atopic dermatitis (AD) offer additional options for clinical treatment.
Qiwei Liao, Hanwen Pan, Yixin Guo, Yuxiang Lan, Zhuo Huang, Peiyi Wu   +5 more
doaj   +1 more source

EASI p-EASI:Predicting Disease Severity in Patients with Atopic Dermatitis Treated with Tralokinumab [PDF]

, 2022
Da Rosa, Joel Correa, de Wijs, Linde E.M., Dik, Willem A., Hijnen, Dirk Jan, Olydam, Jill I., Røpke, Mads A.   +5 more
core   +2 more sources

Older Patients with Atopic Dermatitis Show More Pronounced Early Clinical Improvement with Tralokinumab: A Single-Center Retrospective Real-World Study. [PDF]

J Clin Med
Sato E, Obonai N, Koga M, Sibayama Y, Imafuku S.   +4 more
europepmc   +1 more source

Novel methods of treating atopic dermatitis [PDF]

Atopic dermatitis is a long-term inflammatory skin disease caused by factors such as skin barrier dysfunction and immune system dysregulation . Currently, the first-line treatment for atopic dermatitis involves the use of topical glucocorticosteroids ...
Choinka, Martyna, Kalisiak, Jakub, Karasińska, Dominika, Komarów, Małgorzata, Konopka, Agata, Lissak, Karina, Szczepaniak, Zuzanna, Wdowiak, Natalia   +7 more
core   +1 more source

Breakthrough in Pediatric Atopic Dermatitis Therapy: The Role of Monoclonal Antibodies as a New Hope for Targeted Treatment in Children [PDF]

Aims: Atopic dermatitis (AD) is a prevalent skin condition affecting children of all ages and ethnicities. The aim of this review paper is to explore emerging treatments for atopic dermatitis, with a focus on the latest advancements in monoclonal ...
Domagała, Wojciech, Pilarz, Anna, Salamon, Dariusz, Sojka, Aleksandra, Sosin, Julia, Stachowiak, Julia, Zwierzchowska, Maria   +6 more
core   +1 more source

Long-Term, Site-Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72-Week Real-World Study. [PDF]

J Dermatol
Shiba M, Hagino T, Uchiyama A, Saeki H, Fujimoto E, Motegi SI, Kanda N.   +6 more
europepmc   +1 more source

A Review of Biologic Therapies for Refractory Atopic Dermatitis [PDF]

Atopic Dermatitis (AD) is one of the most common skin conditions, affecting approximately 10% of all individuals in the United States. Existing therapies for AD include emollients, moisturizers, topical corticosteroids, phototherapy, and more.
Bogert, Camryn
core   +1 more source

Risk assessment of asthma and allergic rhinitis in atopic dermatitis patients treated with biologics and JAK inhibitors: a systematic review and network meta-analysis of randomized controlled trials. [PDF]

BMC Med
Zeng L, Zhou T, Zhang L, Xian M, Zhu Z, Liu J, Fu S, Luo H, Li J.   +8 more
europepmc   +1 more source

Tralokinumab for the Treatment of Adult Atopic Dermatitis in Special Populations

Journal of Asthma and Allergy
Luca Potestio,1,* Cataldo Patruno,2,* Stefano Dastoli,2 Claudio Brescia,1 Maddalena Napolitano1 1Section of Dermatology Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 2Department of Health Sciences ...
Potestio L, Patruno C, Dastoli S, Brescia C, Napolitano M   +4 more
doaj  

Biologic Monotherapies for Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Bayesian Network Meta-Analysis of Established and Investigational Agents. [PDF]

Cureus
Babul A, Mehta D, Soliman Y, Hussain M, Babul N.   +4 more
europepmc   +1 more source